vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and DiamondRock Hospitality Co (DRH). Click either name above to swap in a different company.
DiamondRock Hospitality Co is the larger business by last-quarter revenue ($258.2M vs $139.2M, roughly 1.9× ADMA BIOLOGICS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 5.6%, a 29.9% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 1.3%). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs -8.6%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
DiamondRock Hospitality Co is a US-based real estate investment trust owning and operating a portfolio of premium upscale hotels and resorts. Its properties are mainly located in major urban tourist and business hubs nationwide, catering to both leisure and corporate clientele seeking high-quality accommodation services.
ADMA vs DRH — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $258.2M |
| Net Profit | $49.4M | $14.5M |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | 11.1% |
| Net Margin | 35.5% | 5.6% |
| Revenue YoY | 18.4% | 1.3% |
| Net Profit YoY | -55.9% | 22.0% |
| EPS (diluted) | $0.20 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $258.2M | ||
| Q4 25 | $139.2M | $274.5M | ||
| Q3 25 | $134.2M | $285.4M | ||
| Q2 25 | $122.0M | $305.7M | ||
| Q1 25 | $114.8M | $254.9M | ||
| Q4 24 | $117.5M | $279.1M | ||
| Q3 24 | $119.8M | $285.1M | ||
| Q2 24 | $107.2M | $309.3M |
| Q1 26 | — | $14.5M | ||
| Q4 25 | $49.4M | $26.2M | ||
| Q3 25 | $36.4M | $22.5M | ||
| Q2 25 | $34.2M | $40.8M | ||
| Q1 25 | $26.9M | $11.9M | ||
| Q4 24 | $111.9M | $-11.2M | ||
| Q3 24 | $35.9M | $26.4M | ||
| Q2 24 | $32.1M | $24.5M |
| Q1 26 | — | — | ||
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — |
| Q1 26 | — | 11.1% | ||
| Q4 25 | 45.1% | 8.9% | ||
| Q3 25 | 38.0% | 8.1% | ||
| Q2 25 | 35.1% | 13.7% | ||
| Q1 25 | 30.4% | 4.3% | ||
| Q4 24 | 32.6% | -3.7% | ||
| Q3 24 | 33.1% | 9.5% | ||
| Q2 24 | 36.6% | 8.4% |
| Q1 26 | — | 5.6% | ||
| Q4 25 | 35.5% | 9.5% | ||
| Q3 25 | 27.1% | 7.9% | ||
| Q2 25 | 28.1% | 13.4% | ||
| Q1 25 | 23.4% | 4.7% | ||
| Q4 24 | 95.2% | -4.0% | ||
| Q3 24 | 30.0% | 9.3% | ||
| Q2 24 | 29.9% | 7.9% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.20 | $0.12 | ||
| Q3 25 | $0.15 | $0.10 | ||
| Q2 25 | $0.14 | $0.18 | ||
| Q1 25 | $0.11 | $0.04 | ||
| Q4 24 | $0.45 | $-0.06 | ||
| Q3 24 | $0.15 | $0.11 | ||
| Q2 24 | $0.13 | $0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $39.3M |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $1.4B |
| Total Assets | $624.2M | $3.0B |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $39.3M | ||
| Q4 25 | $87.6M | $68.1M | ||
| Q3 25 | $61.4M | $145.3M | ||
| Q2 25 | $90.3M | $52.4M | ||
| Q1 25 | $71.6M | $100.6M | ||
| Q4 24 | $103.1M | $81.4M | ||
| Q3 24 | $86.7M | $75.3M | ||
| Q2 24 | $88.2M | $125.2M |
| Q1 26 | — | — | ||
| Q4 25 | $72.1M | $1.1B | ||
| Q3 25 | $72.4M | $1.1B | ||
| Q2 25 | — | $1.0B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | $72.3M | $1.1B | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | — | $1.2B |
| Q1 26 | — | $1.4B | ||
| Q4 25 | $477.3M | $1.4B | ||
| Q3 25 | $431.2M | $1.6B | ||
| Q2 25 | $398.3M | $1.6B | ||
| Q1 25 | $373.4M | $1.6B | ||
| Q4 24 | $349.0M | $1.6B | ||
| Q3 24 | $231.9M | $1.6B | ||
| Q2 24 | $188.3M | $1.6B |
| Q1 26 | — | $3.0B | ||
| Q4 25 | $624.2M | $3.0B | ||
| Q3 25 | $568.7M | $3.1B | ||
| Q2 25 | $558.4M | $3.1B | ||
| Q1 25 | $510.6M | $3.1B | ||
| Q4 24 | $488.7M | $3.2B | ||
| Q3 24 | $390.6M | $3.2B | ||
| Q2 24 | $376.4M | $3.2B |
| Q1 26 | — | — | ||
| Q4 25 | 0.15× | 0.76× | ||
| Q3 25 | 0.17× | 0.70× | ||
| Q2 25 | — | 0.65× | ||
| Q1 25 | — | 0.70× | ||
| Q4 24 | 0.21× | 0.69× | ||
| Q3 24 | — | 0.67× | ||
| Q2 24 | — | 0.71× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | — |
| Free Cash FlowOCF − Capex | $34.6M | — |
| FCF MarginFCF / Revenue | 24.8% | — |
| Capex IntensityCapex / Revenue | 0.8% | — |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $35.6M | $67.9M | ||
| Q3 25 | $13.3M | $74.6M | ||
| Q2 25 | $21.1M | $73.6M | ||
| Q1 25 | $-19.7M | $27.6M | ||
| Q4 24 | $50.2M | $75.8M | ||
| Q3 24 | $25.0M | $61.7M | ||
| Q2 24 | $45.6M | $55.7M |
| Q1 26 | — | — | ||
| Q4 25 | $34.6M | $47.3M | ||
| Q3 25 | $-1.1M | $54.9M | ||
| Q2 25 | $18.7M | $57.9M | ||
| Q1 25 | $-24.4M | $2.0M | ||
| Q4 24 | $47.5M | $52.6M | ||
| Q3 24 | $24.0M | $39.0M | ||
| Q2 24 | $43.6M | $38.8M |
| Q1 26 | — | — | ||
| Q4 25 | 24.8% | 17.2% | ||
| Q3 25 | -0.8% | 19.2% | ||
| Q2 25 | 15.3% | 18.9% | ||
| Q1 25 | -21.2% | 0.8% | ||
| Q4 24 | 40.4% | 18.9% | ||
| Q3 24 | 20.0% | 13.7% | ||
| Q2 24 | 40.7% | 12.5% |
| Q1 26 | — | — | ||
| Q4 25 | 0.8% | 7.5% | ||
| Q3 25 | 10.7% | 6.9% | ||
| Q2 25 | 2.0% | 5.1% | ||
| Q1 25 | 4.1% | 10.0% | ||
| Q4 24 | 2.3% | 8.3% | ||
| Q3 24 | 0.9% | 7.9% | ||
| Q2 24 | 1.9% | 5.5% |
| Q1 26 | — | — | ||
| Q4 25 | 0.72× | 2.59× | ||
| Q3 25 | 0.36× | 3.31× | ||
| Q2 25 | 0.62× | 1.80× | ||
| Q1 25 | -0.73× | 2.33× | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | 2.33× | ||
| Q2 24 | 1.42× | 2.27× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
DRH
| Rooms | $164.1M | 64% |
| Food and beverage | $67.2M | 26% |
| Other | $26.9M | 10% |
